Volume Insights on Therapeutic Apheresis Sector
The global therapeutic apheresis sector volume projection was valued at 710 thousand procedures in 2023 and is projected to reach 1,597 thousand procedures by 2035, registering a CAGR of 7.0% from 2024 to 2035.
Volume Insights - A Strategic Overview
Allied Market Research announces the release of its comprehensive analysis of global volume of therapeutic apheresis procedures. Therapeutic apheresis is a medical procedure that selectively removes specific components from a patient’s blood to treat various diseases. It is used for conditions such as autoimmune disorders, hematologic diseases, and metabolic disorders by eliminating harmful substances such as antibodies, toxins, or excess cells.
The report highlights therapeutic apheresis sector volume application and rise in the number of therapeutic apheresis procedures, especially across key regions and countries. Demand for procedures has grown significantly, driven by rise in prevalence of autoimmune and hematologic disorders, increase in adoption of apheresis in critical care, and advancements in apheresis technologies. In addition, favorable reimbursement policies and expanding healthcare infrastructure further drives the demand for therapeutic procedures.
Growth in adoption of therapeutic apheresis procedures is attributed to rise in prevalence of autoimmune and hematologic disorders, increase in use of apheresis in organ transplant preparation and neurological conditions, advancements in apheresis technologies, and supportive government policies promoting access to specialized treatment options. In addition, rise in awareness among healthcare providers and patients about the clinical benefits of apheresis is contributing to rise in demand for procedures across both developed and emerging regions.
The global therapeutic apheresis sector volume projection is expected to grow from 710 thousand procedures in 2023 to 1,597 thousand procedures by 2035, registering a CAGR of 7.0% during the forecast period. Rapid expansion is supported by increase in prevalence of hematologic disorders, advancements in apheresis technology, and rise in adoption of therapeutic plasma exchange in critical care.
Regional Therapeutic Apheresis Sector Volume Growth
Asia-Pacific dominated the therapeutic apheresis sector volume with 45.2% share in 2023 and 7.7% CAGR, while North America, Europe, and LAMEA are expected to show strong growth at 5.6%, 6.4%, and 7.3% CAGR, respectively, driven by increase in awareness of apheresis procedures, and rise in demand for personalized medicine.
The regional analysis highlights significant variations in adoption trends and field potential across the globe. Asia-Pacific leads the therapeutic apheresis volume share, contributing to over 45.2% of the total procedures in 2023 and is expected to grow at a CAGR of 7.7%, driven by rise in geriatric population, increase in healthcare expenditure, and rapid expansion of advanced medical facilities. North America, led by the U.S. and Canada, is projected to maintain steady growth at a 5.6% CAGR, fueled by a well-established healthcare infrastructure, increase in adoption of apheresis in chronic disease management, and strong research and development investments. Europe, with key players such as Germany and France, is expected to witness 6.4% CAGR, supported by increasing government funding for advanced therapies, rise in prevalence of hematologic and neurological disorders, and rise in investments in healthcare innovation. Meanwhile, LAMEA offers a significant growth opportunity with 7.3% CAGR, driven by improving healthcare infrastructure, increase in awareness and adoption of apheresis procedures, and rise in investments in medical technology.
Therapeutic Apheresis Sector Volume Forecast Growth, By Region, 2023-2035 (Thousand)
Region | 2023 | 2028 | 2035 | CAGR (2024–2035) |
North America | 155 | 207 | 300 | 5.6% |
Europe | 168 | 232 | 356 | 6.4% |
Asia-Pacific | 321 | 471 | 788 | 7.7% |
LAMEA | 65 | 94 | 152 | 7.3% |
Total | 710 | 1,003 | 1,597 | 7.0% |
Source: AMR Analysis
Therapeutic Apheresis Country Sector Sales
China and the U.S. lead the therapeutic apheresis sector sales volume, and are projected to reach 252 thousand procedures and 281 thousand procedures by 2035 at 8.6% and 5.6% CAGR, respectively, while India (9.9% CAGR) and Brazil (6.7% CAGR), supported by increase in healthcare investments, rise in prevalence of hematologic and autoimmune disorders, and expanding access to advanced medical treatments.
The report identifies China and the U.S. as the largest contributors to the therapeutic apheresis sector in terms of volume. China, with its extensive landscape and growth in emphasis on sustainable practices, is projected to reach 252 thousand procedures by 2035, achieving a CAGR of 8.6%. The U.S., on the other hand, remains an important player in North America, witnessing a steady 5.6% CAGR and accounting for 281 thousand procedures by 2035.
Emerging countries such as India and Brazil are expected to drive significant growth due to their expanding healthcare infrastructure, increase in prevalence of blood-related disorders, and rise in adoption of advanced therapeutic apheresis procedures. India, benefiting from a rapidly expanding healthcare sector, increasing government investments in advanced medical treatments, and growing prevalence of hematologic and autoimmune disorders is expected to register a CAGR of 9.9%, the highest among major countries. Brazil is projected to grow at a CAGR of 6.7% supported by its expanding healthcare industry.
Therapeutic Apheresis Sector Volume Share, By Country, 2023-2035 (Thousand)
Country | 2023 | 2028 | 2035 | CAGR (2024-2035) |
China | 94 | 143 | 252 | 8.6% |
U.S. | 145 | 193 | 281 | 5.6% |
India | 19 | 32 | 60 | 9.9% |
Canada | 6 | 8 | 12 | 5.3% |
Brazil | 16 | 22 | 34 | 6.7% |
Mexico | 4 | 5 | 7 | 4.9% |
Germany | 33 | 47 | 75 | 6.9% |
Source: AMR Analysis
Key Highlights by Stakeholders
Highlighting the significance of this report, Anshul Mishra, Associate Vice-President of Allied Market Research, stated, “Rise in prevalence of autoimmune, hematologic, and neurological disorders, and rise in technological advancements are the major factors that drive the demand for therapeutic apheresis procedures. Our latest report captures the market's dynamics, providing actionable insights for stakeholders aiming to capitalize on this opportunity.”
He further added, “Asia-Pacific, with its rapid healthcare expansion, remains a key market for therapeutic apheresis. Meanwhile, North America and Europe are experiencing steady growth due to advancements in apheresis technologies, rise in adoption of blood purification therapies, and improved reimbursement frameworks. In addition, emerging countries are showing high-growth potential, fueled by increase in healthcare investments and growing medical tourism. With this comprehensive analysis, we aim to empower our clients with the knowledge needed to make informed business decisions.”
Therapeutic Apheresis Sector Volume Trends
The report also emphasizes the growing role of advanced therapeutic apheresis solutions in addressing the rise in demand for effective and patient-friendly treatment options. With increasing awareness of hematologic and autoimmune disorders, alongside the need for precise and targeted blood purification therapies, the adoption of automated and AI-integrated apheresis systems is expected to accelerate in the coming years. This shift is pushing manufacturers to develop innovative solutions that enhance clinical efficiency, improve patient safety, and optimize treatment outcomes.
In addition, technological innovations such as AI-driven apheresis monitoring, wearable blood filtration devices, and precision-targeted plasma exchange systems are shaping the therapeutic apheresis sector. The integration of machine learning in real-time blood composition analysis enhances procedural accuracy, enabling healthcare professionals to optimize apheresis treatments for various medical conditions. These advancements are expected to fuel demand for highly efficient and patient-centric apheresis solutions.
Furthermore, the study explores the impact of healthcare policies and reimbursement frameworks on market dynamics. As healthcare systems worldwide prioritize advanced blood purification strategies, increased funding and favorable reimbursement policies are driving accessibility to cutting-edge apheresis technologies. This shift is crucial in expanding treatment availability, improving patient outcomes, and encouraging the adoption of next-generation therapeutic apheresis systems.
Healthcare stakeholders should use the report’s insights to grab new opportunities and plan ahead.
About Allied Market Research
Allied Market Research is a full-service market research and business consulting firm, which provides actionable insights and strategic recommendations to help clients make informed decisions and achieve sustainable growth. For more inquiries, please visit alliedmarketresearch.com
